Intermittent hormone therapy

Updated: Jun 30

also called intermittent Androgen Deprivation Therapy

also called intermittent ADT


Taking breaks in hormone therapy


Continuous hormone therapy


It was hoped intermittent hormone therapy would make you last longer.

  • It doesn't.

It was hoped intermittent hormone therapy would be better for your bones, for the glands that produce hormones to regulate your metabolism, to help with your thinking.

  • It doesn't.

It does

  • produce more thrombotic events (blood clots that can move to the brain or lungs).

  • produce more ischemic events (slowing of blood flow, worst if it slows blood flow to the heart).

Despite these risks, if your side effects from continuous hormone therapy are too bad, your doctor may recommend, or you may elect to take, intermittent hormone therapy.

The study that showed that intermittent hormone therapy was no better than continuous hormone therapy

Hussain, M., Tangen, C. M., Berry, D. L., Higano, C. S., Crawford, E. D., Liu, G., Wilding, G., Prescott, S., Kanaga Sundaram, S., Small, E. J., Dawson, N. A., Donnelly, B. J., Venner, P. M., Vaishampayan, U. N., Schellhammer, P. F., Quinn, D. I., Raghavan, D., Ely, B., Moinpour, C. M., Vogelzang, N. J., … Thompson, I. M., Jr (2013). Intermittent versus continuous androgen deprivation in prostate cancer. The New England journal of medicine, 368(14), 1314–1325. 

[There were not enough advanced men in the study to determine that continuous was definitely better than intermittent for advanced men. But, in this group of advanced men, those on continuous hormone therapy lived an average of 14 months longer than those on intermittent hormone therapy.]

The study that identified the problems that intermittent hormone therapy added


Contrary to our hypothesis that intermittent ADT would reduce long-term health-related events compared with continuous ADT, we found that older men assigned to intermittent ADT had no apparent reduction in bone, endocrine, or cognitive events and an increased incidence of ischemic and thrombotic events.

Hershman, D. L., Unger, J. M., Wright, J. D., Ramsey, S., Till, C., Tangen, C. M., Barlow, W. E., Blanke, C., Thompson, I. M., & Hussain, M. (2016). Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA oncology, 2(4), 453–461. 

Recent Posts

See All

Don't stop abi or enz too soon

A number of doctors advise that a man should get as much benefit as he can from each treatment before he moves onto the next. Zytiga (abiraterone) and Xtandi (enzalutamide), in particular should not b

PCRI conference 11-12 September 2021

The biggest prostate cancer patient conference in the world is run by the Prostate Cancer Research Institute (PCRI) each September. It attracts the worlds top Prostate Cancer doctors, and this year is

Hormone therapy (ADT) and Covid

Testosterone suppresses the immune system. Males have more testosterone than women. So women have stronger immune systems than men. When it comes to infections, women get fewer, and less severe compli